Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs

Patent ExpiryAntibody-Based DrugsPositive

AI Analysis

Summary

Vesselon received U.S. patent for compositions and methods enabling antibody-based drugs to deliver 6X more drug to tumors while reducing off-target tissue exposure, potentially improving the therapeutic index of antibody therapies.

Outcome Details

U.S. Patent Number 12,714,676 issued for compositions and methods for targeted delivery of antibody-based drugs

Importance:5/10

Sentiment:

0.60

patent issuanceantibody drug deliverytargeted therapyintellectual property

Related Companies

$GLSI $CBDY $DMIIR

Read the original article

Published by PR Newswire Pharma on August 26, 2026 4:03 PM

Read Original